BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to conventional staging in women with presumed early-stage endometrial cancer (The BIOMEC trial)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505991-31-00

Acronym

BIOMEC trial

Enrollment

1037

Registered

2023-09-29

Start date

2024-04-30

Completion date

2024-06-25

Last updated

2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ENDOMETRIAL CANCER

Brief summary

Overall survival

Detailed description

Recurrence-free survival, EORTC QLQ-C30, QLQ-EN24 and EQ5D-5L Score, LYMQOL and volume measurement, lymphosintigraphy result, Clinical Frailty Scale-9 score (1-9), As measured by CT and applicable software (e.g., Coreslicer, Slice-o-matic etc.), QALY, cost per patient, 30-day post-operative complications and adverse events

Interventions

DRUGPACLITAXEL

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Recurrence-free survival, EORTC QLQ-C30, QLQ-EN24 and EQ5D-5L Score, LYMQOL and volume measurement, lymphosintigraphy result, Clinical Frailty Scale-9 score (1-9), As measured by CT and applicable software (e.g., Coreslicer, Slice-o-matic etc.), QALY, cost per patient, 30-day post-operative complications and adverse events	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026